3 Branded Generics Pharma Company, Pharma Formulations and Custom Synthesis Company and Integrated Apparel Maker Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Laurus Labs and KPR Mill
- October 30, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Emcure Pharmaceuticals, Laurus Labs and KPR Mill: ROE of 15.2% to 18.7% and FY22 to FY26 revenue CAGR of 8.4% to 12.1%. Prices as of 29 Oct 2026.
Quick Answer
The three generic, custom pharma and apparel stocks to watch are Emcure Pharmaceuticals, Laurus Labs and KPR Mill. Their return on equity ranges from 15.2% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 12.1%. Emcure Pharmaceuticals leads on both return on equity at 18.7% and revenue growth at 12.1% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.
Generic, custom pharma and apparel stocks offer a focused view of a sector where demand keeps widening. Emcure Pharmaceuticals, Laurus Labs and KPR Mill cover a branded generics pharma company, a pharma formulations and custom synthesis company and an integrated apparel maker.
This list covers three generic, custom pharma and apparel stocks with complete current figures: Emcure Pharmaceuticals, Laurus Labs and KPR Mill. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generic, Custom Pharma and Apparel Stocks?
Generic, custom pharma and apparel stocks are listed companies that sell branded generics in India and overseas, make formulations, custom synthesis products and biotechnology offerings and spin yarn, knit fabric and stitch garments for global brands. Their earnings depend on export orders, approvals and product mix.
Generic, Custom Pharma and Apparel Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 1,865 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| Laurus Labs | 2,244 | 111,434 | 102.2 | 36.0 | 16.8 | 0.48 |
| KPR Mill | 1,082.7 | 34,974 | 38.3 | 33.8 | 15.2 | 0.10 |
On valuation, Emcure Pharmaceuticals trades at a P/E below the industry P/E, while Laurus Labs and KPR Mill trade above it, which reflects the growth the market already expects. Readers comparing generic, custom pharma and apparel stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generic, custom pharma and apparel stocks can use the coming numbers to test whether growth is holding.
Why Do Generic, Custom Pharma and Apparel Stocks Have a Strong Roadmap in India?
Generic, custom pharma and apparel stocks have a strong roadmap in India because steady medicine demand, global buyers adding Indian suppliers and brands sourcing garments from integrated makers keep widening the market for these export focused companies.
- Global buyers. Overseas customers add Indian partners.
- Medicine demand. Health needs bring repeat orders.
- Integration. Yarn to garment control supports quality.
Why Emcure Pharmaceuticals Features Among These Generic, Custom Pharma and Apparel Stocks
Among the generic, custom pharma and apparel stocks on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why Laurus Labs Features Among These Generic, Custom Pharma and Apparel Stocks
Among the medicine and garment exporters shares on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.
In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%.
Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.
Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.
Why KPR Mill Features Among These Generic, Custom Pharma and Apparel Stocks
Among the three companies on this list, KPR Mill is a Coimbatore-based, vertically integrated apparel maker that spins yarn, knits fabric and stitches garments for global brands. It also runs sugar and ethanol operations and a growing retail business.
The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 34,974 crore. The stock trades at a P/E of 38.3, above the industry P/E of 33.8.
Revenue rose from Rs 4,910 crore in FY22 to Rs 6,784 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 815 crore in FY25 to Rs 866 crore in FY26, a rise of 6.3%. In the June 2026 quarter, revenue grew 9.3% year on year to Rs 1,970 crore, while net profit rose 21.6% to Rs 259 crore.
Roadmap: The company is adding garment and fabric capacity and deepening ties with large international apparel buyers. Its control over each step from yarn to garment supports delivery speed and quality.
What to watch: Track garment export orders, capacity additions and the progress of the retail business.
Emcure Pharmaceuticals vs Laurus Labs vs KPR Mill on Key Financials
The table below sets the three generic, custom pharma and apparel stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| Laurus Labs | 4,951 | 6,868 | 8.5% | 890 | 13.0% |
| KPR Mill | 4,910 | 6,784 | 8.4% | 866 | 12.8% |
Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Emcure Pharmaceuticals combines the largest FY26 revenue at Rs 9,335 crore with the fastest revenue growth, a 12.1% compound annual rate. A useful habit with generic, custom pharma and apparel stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Emcure Pharmaceuticals | 2,104 | 2,583 | 22.7% |
| Laurus Labs | 1,580 | 2,035 | 28.8% |
| KPR Mill | 1,802 | 1,970 | 9.3% |
Key Risks to Check Before Investing in Generic, Custom Pharma and Apparel Stocks
Every theme carries risks that deserve a check before any decision. For these generic, custom pharma and apparel stocks, the main points are: Long-term medicine and garment exporters shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter generic, custom pharma and apparel stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Generic, Custom Pharma and Apparel Stocks
Generic, custom pharma and apparel stocks reward patient research into demand, execution and financial strength. Emcure Pharmaceuticals, Laurus Labs and KPR Mill each have a clear plan to grow. Based on the 29 October 2026 close, Emcure Pharmaceuticals trades at Rs 1,865, Laurus Labs at Rs 2,244 and KPR Mill at Rs 1,082.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these generic, custom pharma and apparel stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track generic, custom pharma and apparel stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are generic, custom pharma and apparel stocks?
Ans. Generic, custom pharma and apparel stocks are listed companies that sell branded generics in India and overseas, make formulations, custom synthesis products and biotechnology offerings and spin yarn, knit fabric and stitch garments for global brands. Their earnings depend on export orders, approvals and product mix. This list looks at three of them, Emcure Pharmaceuticals, Laurus Labs and KPR Mill, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.
Which generic, custom pharma and apparel stocks are covered in this list?
Ans. This list covers Emcure Pharmaceuticals, Laurus Labs and KPR Mill. Based on the 29 October 2026 close, Emcure Pharmaceuticals traded at Rs 1,865, Laurus Labs at Rs 2,244 and KPR Mill at Rs 1,082.7. Their return on equity ranges from 15.2% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 12.1%.
Why do generic, custom pharma and apparel stocks have a strong future roadmap in India?
Ans. Generic, custom pharma and apparel stocks have a strong roadmap in India because steady medicine demand, global buyers adding Indian suppliers and brands sourcing garments from integrated makers keep widening the market for these export focused companies. The main drivers are as follows. Global buyers. Overseas customers add Indian partners. Medicine demand. Health needs bring repeat orders. Integration. Yarn to garment control supports quality. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women’s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has Laurus Labs performed financially?
Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
How has KPR Mill performed financially?
Ans. Revenue rose from Rs 4,910 crore in FY22 to Rs 6,784 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 815 crore in FY25 to Rs 866 crore in FY26, a rise of 6.3%. In the June 2026 quarter, revenue grew 9.3% year on year to Rs 1,970 crore, while net profit rose 21.6% to Rs 259 crore. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 34,974 crore. The stock trades at a P/E of 38.3, above the industry P/E of 33.8. Looking ahead, the company is adding garment and fabric capacity and deepening ties with large international apparel buyers. Its control over each step from yarn to garment supports delivery speed and quality.
What risks should investors check before buying generic, custom pharma and apparel stocks?
Ans. Investors should check a few risks before buying generic, custom pharma and apparel stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of generic, custom pharma and apparel stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.